

NEW FRONTIERS IN URO-ONCOLOGY

CENTRO CULTURAL DE BELÉM, LISBON • OCTOBER 18th 2019
Chairmen: Luis Costa MD, PhD & Tomé Lopes MD, PhD

INSCRIÇÃO
OBRIGATÓRIA

— www.eruditus.pt —

ORGANIZAÇÃO



SECRETARIADO



APOIOS



Bristol-Myers Squibb



PROGRAM



09:00 | Registration

09:30 | Opening – Luís Costa, Tomé Lopes

PROSTATE SESSION

Chairs: Luis Campos Pinheiro, Nuno Vau

09:45 | Paradigm changes in Metastatic Castration Sensitive Prostate Cancer – Isabel Fernandes

10:15 | Liquid Biopsies in Advanced Prostate Cancer – André Mansinho

10:45 | **COFFEE BREAK** 

11:15 | New perspectives on imaging prostate cancer – Adalgisa Guerra, Sofia Vaz

12:00 | Metastatic Castration Resistant Prostate Cancer (mCRPC): state of the art and future perspectives – Daniel Petrylak

12:30 | Clinical Case Presentation – José Dias

12:45 | Discussion

13:00 | **LUNCH** 

NON-PROSTATE SESSION

Chairs: Arnaldo Figueiredo, Isabel Fernandes

14:30 | Surgical management of Renal Cell Carcinoma and CARMENA Trial: practice changing? – Tito Leitão

15:00 | Reviewing pathology concepts in renal cell carcinoma – Rui Henrique

15:30 | **COFFEE BREAK** 

16:00 | Targeted therapy in Uro-Oncology – Pedro Barata

16:30 | Immunotherapy in Uro-Onology: what is standard and what is a vision – Emiliano Calvo

17:00 | Clinical Case Presentation – Daniela Macedo

17:15 | Discussion

17:30 | Closure – Luís Costa

Adalgisa Guerra (Hospital da Luz), André Mansinho (Hospital de Santa Maria & Instituto de Medicina Molecular & Faculdade de Medicina de Lisboa), Arnaldo Figueiredo (CHUC, FMUC – Coimbra), Daniel Petrylak (Yale School of Medicine New Haven), Emiliano Calvo (Hospital Universitario HM Sanchinarro Madrid), Isabel Fernandes (CH Lisboa Norte, Hospital de Santa Maria – Lisboa), José Dias (CH Lisboa Norte, Hospital de Santa Maria – Lisboa), Luis Campos Pinheiro (CH Lisboa Central, Hospital São José), Luís Costa (Hospital de Santa Maria & Instituto de Medicina Molecular & Faculdade de Medicina de Lisboa), Nuno Vau (Fundação Champalimaud), Pedro Barata (Tulane Cancer Center/Genitourinary Cancers em New Orleans), Rui Henrique (Instituto Português de Oncologia do Porto), Sofia Vaz (Fundação Champalimaud), Tito Leitão (CH Lisboa Norte, Hospital de Santa Maria – Lisboa), Tomé Lopes (CH Lisboa Norte, Hospital de Santa Maria – Lisboa).